Evaluating the effectiveness of a new imaging method for prostate cancer recurrence
Official title: Diagnostic Performance and Clinical Impact of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer: a Real-World Evidence from a Monocentric, Prospective Observational Phase-4-Trial
Run by Heinrich-Heine University, Duesseldorf · NCT06657131 · Data updated 2026-11-12
This study is testing a new imaging method to see if it can help doctors better detect prostate cancer recurrence in patients who have already been treated.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 250 (estimated) |
| Sponsor | Heinrich-Heine University, Duesseldorf Academic / other |
| Locations | 1 site (Düsseldorf, North Rhine-Westphalia) |
| Status | Recruiting |
| Started | November 1, 2024 |
| Main results expected | November 30, 2026 |
| Study ends | November 30, 2028 |
| Registry record updated | January 17, 2025 |
| Trial ID | NCT06657131 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with a history of prostate cancer who are experiencing biochemical recurrence and are undergoing [18F]PSMA-1007 PET imaging as part of their clinical care.
✕Probably not a fit
Patients who do not meet the inclusion criteria or have technical flaws in the imaging acquisition protocol may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the diagnostic performance of [18F]PSMA-1007 in patients with biochemical recurrence of prostate cancer after radical treatment. Following its approval in several EU countries, including Germany, the study aims to generate real-world evidence on the clinical impact of this imaging method in everyday practice. By analyzing diagnostic accuracy and creating a comprehensive database, the study seeks to optimize management strategies for prostate cancer patients and potentially enhance the use of PSMA-PET diagnostics.
Why it matters
Potential benefit: If successful, this study could significantly improve the diagnostic accuracy and management of prostate cancer patients experiencing biochemical recurrence.
How similar studies have gone: Other studies have shown promising results with PSMA diagnostics, indicating a potential for success in this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed Consent * Conduct of \[18F\]PSMA-1007 PET Imaging in the context of regular clinical care Exclusion Criteria: * Technical Flaws in the acquisition protocol
Where it's running
-
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf
Düsseldorf, North Rhine-Westphalia, Germany Recruiting
Study contacts
- Study coordinator: Emil Novruzov, Medical Doctor
- Email: Emil.Novruzov@med.uni-duesseldorf.de
- Phone: (+49)211 8118540
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Shorter Salvage Radiotherapy after Prostate Surgery for Recurrent Prostate Cancer
This study tests whether a shorter, 4-week salvage radiotherapy schedule is as safe and effective as the standard 5-week schedule for men with prostate cancer that has come back after surgery.
-
Evaluating Fluciclovine PET imaging for recurrent prostate cancer detection
This study is testing if fluciclovine PET scans can help find recurrent prostate cancer in men who had unclear results from previous scans.
-
Registry for prostate cancer treatment and outcomes
This study is tracking the treatment and progress of men with recurrent and advanced prostate cancer to see how different therapies affect their lives over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.